US Researchers to Test RECCE in Expanded SARS-CoV-2 Program
Released
Released
Announcement PDF
ASX Announcement
Leading US Researchers to Test RECCE® Compounds in Expanded SARS-CoV-2
Program
Highlights:
•
International study led by Path BioAnalytics and conducted in a laboratory at a leading academic
institution in the U.S. to evaluate anti-viral activity of RECCE® 327 and new anti-viral formulation
RECCE® 529
•
Expanded program utilising United States Centre for Disease Control (CDC) SARS-CoV-2
clinical isolate SARS-Related Coronavirus 2 Isolate USA-WA1/2020
•
Preliminary data anticipated September 2020
Sydney Australia, 16 July 2020: Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the
Company developing New Classes of Synthetic Anti-infectives, today announced it has entered
into an agreement with Path BioAnalytics Inc (PBA), a precision medicine company based in
Durham, North Carolina, USA, for the study of RECCE® 327 and RECCE® 529 against SARSCoV-2.
Researchers at PBA will evaluate RECCE® 327 and RECCE® 529 against SARS-CoV-2 (the
virus causeing the disease ‘Coronavirus’ or ‘COVID-19’ 1) in an ex vivo respiratory organoid
model system.
The study will be conducted in the state-of-the-art Biosafety Level 3 containment laboratories of
a leading US research university, where the infection of the organoids with SARS-CoV-2 will
take place. The purpose of the study is to evaluate both compound therapies for the prevention
and/or mitigation of SARS-CoV-2 infections in an ex-vivo respiratory model system with
preliminary data anticipated September 2020.
RECCE® 327 is a broad-spectrum synthetic antibiotic formulated using synthetic polymer
technology to treat blood infections and sepsis. RECCE® 529 is a new synthetic polymer
formulation, built upon the Company’s anti-infective expertise.
1 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-
disease-(covid-2019)-and-the-virus-that-causes-it
All intellectual properties are retained by the Company. Following selection for a domestic
program as previously announced, the antiviral potential of Recce’s compounds are now
being tested independently in the US and Australia.
Dr. John Prendergast, Recce Pharmaceuticals Non-Executive Chairman: “The current
pandemic underscores the need for more effective treatment approaches to prevent
infectious diseases. Over the past few months Recce has received a number of expressions
of interest from several universities and research organisations to collaborate on the
development of potential new therapies to address the unmet needs of patients with COVID19. We’re excited to be working with experts at Path BioAnalytics to investigate the potential
effectiveness of Recce’s compounds in treatment of SARS-CoV-2 infection using their
advanced respiratory organoid model system.”
Path BioAnalytics is a precision medicine company dedicated to the advancement of nextgeneration treatments for diseases with high unmet need. PBA is currently focused on using
its industry-leading respiratory organoid technology to evaluate SARS-CoV-2 targeted
treatments on behalf of pharmaceutical and biotechnology companies worldwide. The
company’s respiratory organoids are pseudo-stratefied, differentiated 3D cell cultures derived
from primary respiratory cells that replicate the airway physiology and are amenable to SARSCoV-2 infection. Unlike commonly used model systems, PBA organoid technology does not
place selective pressure on viruses, thus maintaining an accurate representation of viral
infection.
While Recce is delighted that its compounds have been selected for potential investigational
therapies, such selection is not an indication that the compounds are safe or effective for use
in treatment of SARS-CoV-2.
This announcement has been approved for release by Recce Pharmaceuticals Board.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New
Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic
resistant superbugs and emerging viral pathogens.
Recce antibiotics are unique – their potency does not diminish even with repeated use, a common
failure associated with existing antibiotics and their propensity to rapidly succumb to resistant
superbugs.
Patented lead candidate RECCE® 327, wholly owned and manufactured in Australia, has been
developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus
bacteria – including their superbug forms.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under
the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation,
plus 10 years of market exclusivity post approval.
Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials.
Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies
targeting synergistic, unmet medical needs.
Share your feedback
Discover